Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients ...

Treatment with the gene therapy exagamglogene autotemcel led to significant and sustained improvements in health-related ...

Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients with severe sickle cell ...

Earlier this month, we learned 22-year-old Daniel Cressy would become the first person in Louisiana to receive a gene therapy ...

Gene therapy for sickle cell disease may help improve a major contributing factor to stroke risk in patients, reports a new study from St. Jude Children's Research Hospital.

Fifteen-year-old Jayden Wilsey of Falmouth is the first person at Boston Children's Hospital to receive human gene therapy for sickle cell disease, following approval of the therapy in 2024 by the ...

FDA-approved Lyfgenia and CRISPR gene editing therapy Casgevy are effective against sickle cell disease, but the high price poses a challenge.

CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base ...

Patients who received lovo-cel had durable remissions and reductions in vaso-occlusive events, pain crises, and hospitalizations in the longest running gene therapy trial for sickle cell disease.

At 22, Daniel Cressy is making history as Louisiana’s first sickle cell gene therapy patient. The treatment could be a cure ...

Julie Kanter, M.D., (Associate Professor, Hematology and Oncology; Co-director of the UAB Lifespan Comprehensive Sickle Cell Center) and colleagues have been published in the New England Journal of ...

SNS Insider Reveals U.S. Sickle Cell Disease Treatment Market Growth at 17.76% CAGR, Reaching USD 0.92 Billion in 2024 as America Leads Global Innovation in SCD Therapeutics.Austin, Aug. 27, 2025 ...